

pan-Canadian Oncology Drug Review Provincial Advisory Group (PAG) Feedback on a pCODR Expert Review Committee Initial Recommendation

Ibrutinib (Imbruvica) for Chronic Lymphocytic Leukemia/Small Cell Lymphoma

March 5, 2015

# 3 Feedback on pERC Initial Recommendation

Name of the drug indication(s): Ibrutinib (Imbruvica) for CLL/SLL

Endorsed by:

Provincial Advisory Group Acting Chair

Feedback was provided by all nine provinces (Ministries of Health and/or provincial cancer agencies) participating in pCODR.

#### 3.1 Comments on the Initial Recommendation

a) Please indicate if the PAG (either as individual PAG members and/or as a group) agrees or disagrees with the initial recommendation:

\_\_X\_\_\_ Agrees \_\_\_\_\_ Agrees in part \_\_\_\_\_ Disagree

All members providing feedback agree with the recommendation.

- b) Notwithstanding the feedback provided in part a) above, please indicate if the PAG would support this initial recommendation proceeding to final pERC recommendation ("early conversion"), which would occur within 2(two) business days of the end of the consultation period.
  - \_X\_Support conversion to final<br/>recommendation.\_\_\_\_Do not support conversion to final<br/>recommendation.Recommendation does not require<br/>reconsideration by pERC.Recommendation should be<br/>reconsidered by pERC.Recommendation should be<br/>reconsidered by pERC.

All PAG members support conversion of the initial recommendation to final.

c) Please provide feedback on the initial recommendation. Is the initial recommendation or are the components of the recommendation (e.g., clinical and economic evidence) clearly worded? Is the intent clear? Are the reasons clear?

Page		Paragraph,	Comments and Suggested Changes to
Number	Section Title	Line Number	Improve Clarity
1	pERC		Suggestion to remove "with or without
	Recommendation		del(17p)" as it appears to be redundant
4	Summary of pERC	Paragraph#3,	The statement "the use of ibrutinib in
	Deliberatonns	line #3	other lines of therapy" is inconsistent with
			the statement on pg9, paragraph 3, line 2

			"use of ibrutinib in earlier lines of therapy" and the statement on pg 9, paragraph 2, line 2 also states that "pERC agreed that ibrutinib should be used in patients with relapsed or refractory disease regardless of the number of previous lines of therapy". Language should be consistent in its application.
7	Patient values on treatment: Treatment choice, remission, reduced toxicity	Paragraph #4	PAG suggested a clarification for pERC to consider on statement about better patient compliance. IV treatments have the best compliance because the health care system tracks it. PAG understands the intention of pERC may have been to indicate that once a day dosing may result in greater compliance.
8	Drug costs: Continuous once daily dosing, treatment until disease progression, high drug cost	Paragraph #4	PAG noted that ibrutinib is not a one capsule dose; the dose is actually 3 capsules and this may actually be an issue for patient compliance.

### 3.2 Comments related to PAG input

Please provide feedback on any issues not adequately addressed in the initial recommendation based on the PAG input provided at the outset of the review on potential impacts and feasibility issues of adopting the drug within the health system.

Page Number	Section Title	Paragraph, Line Number	Comments related to initial PAG input
			PAG noted that the NOC recently issued by Health Canada includes front-line treatment of patients with CLL with 17p deletion. PAG would like pERC to acknowledge the NOC indications and state that the current submission and the review recommendations only encompass a portion of the NOC and therefore only these should be funded at this time. PAG is seeking a stronger and clearer statement on the use of ibrutinib in the front-line treatment of CLL in patients with the 17p deletion, as there will be perceived agap in the pCODR review.

#### 3.3 Additional comments about the initial recommendation document

Please provide any additional comments:

Page	Section	Paragraph,	Additional Comments
Number	Title	Line Number	
			PAG requested that pERC comment on retreatment with ibrutinib, where patients have had a distant past response to ibrutinib and upon relapse are looking to be treated with a new regimen.

## About Completing This Template

pCODR invites the Provincial Advisory Group (PAG) to provide feedback and comments on the initial recommendation made by the pCODR Expert Review Committee. (See <u>www.pcodr.ca</u> for information regarding review status and feedback deadlines.)

As part of the pCODR re view process, the pCODR Expert Review Committee makes an initial recommendation based on its review of the clinical, economic and patient evidence for a drug. (See <u>www.pcodr.ca</u> for a description of the pCODR process.) The pERC initial recommendation is then posted for feedback and comments from various stakeholders. The pCODR Expert Review Committee welcomes comments and feedback that will help the members understand why the PAG, either as individual PAG members and/or as a group, agrees or disagrees with the pERC initial recommendation. In addition, the members of pERC would like to know if there is any lack of clarity in the document and if so, what could be done to improve the clarity of the information in the pERC initial recommendation. Other comments are welcome as well.

All stakeholders have 10 (ten) business days within which to provide their feedback on the initial recommendation and rationale. If all invited stakeholders agree with the recommended clinical population described in the initial recommendation, it will proceed to a pERC final recommendation by 2 (two) business days after the end of the consultation (feedback) period. This is called an "early conversion" of an initial recommendation to a final recommendation.

If any one of the invited stakeholders does not support the initial recommendation proceeding to a pERC final recommendation, pERC will review all feedback and comments received at the next possible pERC meeting. Based on the feedback received, pERC will consider revising the recommendation document as appropriate. It should be noted that the initial recommendation and rationale for it may or may not change following consultation with stakeholders.

The pERC final recommendation will be made available to the participating provincial and territorial ministries of health and cancer agencies for their use in guiding their funding decisions and will also be made publicly available once it has been finalized.

### Instructions for Providing Feedback

- a) Only members of the PAG can provide feedback on the pERC initial recommendation; delegates must work through the PAG representative to whom they report.
  - a. Please note that only one submission is permitted for the PAG. Thus, the feedback should include both individual PAG members and/or group feedback.
- b) Feedback or comments must be based on the evidence that was considered by pERC in making the pERC initial recommendation. No new evidence will be considered at this part of the review process, however, it may be eligible for a Resubmission.
- c) The template for providing *Provincial Advisory Group (PAG) Feedback on a pERC Initial Recommendation* can be downloaded from the pCODR website. (See <u>www.pcodr.ca</u> for a description of the pCODR process and supporting materials and templates.)
- d) At this time, the template must be completed in English. PAG should complete those sections of the template where they have substantive comments and should not feel obligated to complete every section, if that section does not apply. Similarly, PAG should not feel restricted by the space allotted on the form and can expand the tables in the template as required.

- e) Feedback on the pERC Initial Recommendation should not exceed three (3) pages in length, using a minimum 11 point font on 8 ½" by 11" paper. If comments submitted exceed three pages, only the first three pages of feedback will be forwarded to the pERC.
- f) Feedback should be presented clearly and succinctly in point form, whenever possible. The issue(s) should be clearly stated and specific reference must be made to the section of the recommendation document under discussion (i.e., page number, section title, and paragraph). Opinions from experts and testimonials should not be provided. Comments should be restricted to the content of the initial recommendation.
- g) References to support comments may be provided separately; however, these cannot be related to new evidence. New evidence is not considered at this part of the review process, however, it may be eligible for a Resubmission. If you are unclear as to whether the information you are considering to provide is eligible for a Resubmission, please contact the pCODR Secretariat.
- h) The comments must be submitted via a Microsoft Word (not PDF) document to the pCODR Secretariat by the posted deadline date.
- i) If you have any questions about the feedback process, please e-mail <u>submissions@pcodr.ca</u>.

Note: Submitted feedback may be used in documents available to the public. The confidentiality of any submitted information cannot be protected.